News & Updates
Filter by Specialty:
HK data: SGLT2 inhibitors cut risks of respiratory and renal diseases in T2DM
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risks of respiratory and renal diseases vs dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM), researchers from the University of Hong Kong (HKU) have reported.
HK data: SGLT2 inhibitors cut risks of respiratory and renal diseases in T2DM
29 Mar 2023
Less salt may be fatally counterproductive for people with heart failure
Too little salt is not necessarily better for individuals with heart failure, with the results of a recent meta-analysis suggesting that sodium restriction in this population increases the risk of death.
Less salt may be fatally counterproductive for people with heart failure
24 Mar 2023
Low-carb, high-fat diet: Friend or foe?
Revered by diet enthusiasts as a godsend in the weight loss arena, a low-carbohydrate, high-fat (LCHF*) diet appears to take the opposite pole from a cardiovascular (CV) standpoint, as researchers from Canada found high levels of bad cholesterol and apolipoprotein B (apoB) in individuals who adhered to this dietary pattern.
Low-carb, high-fat diet: Friend or foe?
24 Mar 2023
Metformin–thiazolidinedione combo best bet for AF prevention in T2D
Combination therapy with metformin and thiazolidinedione appears to be the best performing glucose-lowering medication for preventing atrial fibrillation (AF) in patients with type 2 diabetes (T2D), as shown in a study.
Metformin–thiazolidinedione combo best bet for AF prevention in T2D
24 Mar 2023
Coordinated care improves use of CVD-preventive therapies in T2D
A coordinated, multifaceted intervention of assessment, education, and feedback has resulted in an increase in the prescription of recommended, evidence-based therapies in adult patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (CVD), reveals a study presented at ACC 2023.
